

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

溫州康寧醫藥有限公司
Wenzhou Kangning Pharmaceutical Co., Ltd.

The remuneration of the Chairman and executive directors of the Company will be formulated in accordance with relevant regulations, and the remuneration plan will be proposed at the general meeting of the Company for consideration and approval after consideration in accordance with relevant procedures. The non-executive directors will not receive any remuneration from the Company, and the independent non-executive directors will receive remuneration according to the remuneration standard approved by the general meeting of the Company. Details of directors' remuneration are set out in the Company's annual report.

The biographies of the candidates for directors of the third session of the Board are set out in Appendix I to this announcement.

Save as disclosed in the Appendix I, the above candidates of Directors neither held any other directorships in the past three years in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas, nor held any other major appointments and professional qualifications, nor held any position in the Company or its subsidiaries and they have no relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company. At the date of this announcement, save as disclosed in the Appendix I, the above candidates of Directors have no interest in any Share of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Besides, save as disclosed in the Appendix I, there is no information which is discloseable nor are/were the above candidates of Directors involved in any of the matters required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Save for the Appendix I, there is no other matter that needs to be brought to the attention of the Shareholders.

PROPOSED ELECTION OF SHAREHOLDER REPRESENTATIVE SUPERVISOR AND INDEPENDENT SUPERVISORS OF THE THIRD SESSION OF THE SUPERVISORY COMMITTEE

The term of the second session of the supervisory committee (the “**Supervisory Committee**”) of recreation ansmoof implagemeaention od

Supervisles

The following is the list of candidates for the shareholder representative Supervisor and independent Supervisors of the third session of the Supervisors Committee, which has been considered and approved by the Supervisory Committee:

- (1) candidate for shareholder representative Supervisor: Ms. HUANG Jing'ou; and
- (2) candidates for independent Supervisors: Mr. QIAN Chengliang and Mr. CHEN Jian.

The above Supervisor candidates meet the requirements as stipulated in relevant PRC laws, regulations and the Articles, and the Supervisory Committee agreed to propose ordinary resolutions in respect of the above list of candidates for consideration at the AGM.

The Supervisors of the third session of the Supervisors Committee will serve for a term of three years, and the term of office of shareholder representative Supervisor and independent Supervisors will take effect from the date of approval at the AGM. The shareholder representative Supervisor and independent Supervisors will not receive any remuneration or allowance from the Company.

The biographical details of the candidates of the shareholder representative Supervisor and independent Supervisors of the third session of the Supervisory Committee are set out in the Appendix II to this announcement.

Save as disclosed in the Appendix II, the above candidates of Supervisors have not held any other directorships in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas over the past three years and did not held any other major appointments and professional qualifications, nor held any position in the Company or its subsidiaries nor do they have any relationship with any other Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As of the date of this

The current independent non-executive Directors, namely Mr. CHONG Yat Keung, Mr. Huang Zhi and Mr. GOT Chong Key Clevin, will retire upon the expiration of their terms of office as Directors, with effect from the date when the third session of the Board officially takes office. The above-mentioned retiring Directors have confirmed that they have no disagreement with the Board and there are no other matters relating to their retirement that need to be brought to the attention of the Stock Exchange.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
May 14, 2020

As of the date of this announcement, the Company's executive Directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive Directors are Mr. YANG Yang

APPENDIX I – BIOGRAPHICAL DETAILS OF THE PROPOSED DIRECTORS

Executive Directors

Mr. GUAN Weili (管偉立), aged 50, is chairman of the Board and an executive Director. He is primarily responsible for the overall business operation and strategic planning of the Company. He founded the Company in February 1996 and became an executive Director since then. Mr. Guan was appointed as chairman of the Board and an executive Director in September 2014 after the Company was converted into a joint stock limited liability company. Prior to joining the Company, Mr. Guan served as a clinician at Wenzhou Mental Hospital (溫州市精神病院), a local hospital in Wenzhou, from August 1987 to December 1993, where he was primarily responsible for the medical treatment of psychiatric patients. Mr. Guan graduated from Wenzhou Medical University (溫州醫科大學) (previously known as Wenzhou Medical College (溫州醫學院)) in Wenzhou in August 1987, majoring in medical assistance. Mr. Guan obtained his senior business operator certificate from Wenzhou Municipal Bureau of Personnel (溫州市人事局) in December 2007. Mr. Guan is the spouse of Ms. WANG Lianyue and the brother-in-law of Ms. WANG Hongyue and Mr. XU Yi.

As at the date of this announcement, Mr. Guan was deemed to have an interest in 22,144,750 Domestic Shares within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong), of which 18,350,250 Domestic Shares were beneficially owned and 3,794,500 Domestic Shares were in the interest of the spouse.

Ms. WANG Lianyue (王蓮月), aged 51, is our executive Director and general manager. She is primarily responsible for the overall hospital operation and business development of the Company. She joined the Company in January 1998 and has served as our general manager since September 2011 and our executive Director since April 2013. Ms. Wang was appointed as our executive Director again in September 2014 after the Company was converted into a joint stock limited liability company. Prior to joining the Company, from August 1988 to December 1997, she was a nurse at Wenzhou Mental Hospital (溫州市精神病院), where she was primarily responsible for general patient care. Ms. Wang received two associate degrees from Wenzhou Medical University (溫州醫科大學) (previously known as Wenzhou Medical College (溫州醫學院)) in Wenzhou in June 2004 and the Party School of Wenzhou Municipal Committee of the Communist Party of China (中共溫州市委黨校) in Wenzhou in June 2002, where she majored in nursing and economic administration respectively. She graduated from Online Education College of Xi'an Jiaotong University (西安交通大學網絡教育學院), through long-distance education, with a bachelor's degree in law in July 2007. She also completed part-time hospital management courses at the China Europe International Business School (中歐國際工商學院) in Shanghai in September 2006. She was accredited as secondary psychological consultant (二級心理諮詢師) by the Ministry of Human Resources and Social Security of China (人力資源和社會保障部) in December 2004. Ms. Wang is the spouse of Mr. GUAN Weili, the sister of Ms. WANG Hongyue and the sister-in-law of Mr. XU Yi.

As at the date of this announcement, Ms. Wang was deemed to have an interest in 22,149,750 Domestic Shares within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong), of which 3,794,500 Domestic Shares were beneficially owned and 18,350,250 Domestic Shares were in the interest of the spouse.

Ms. WANG Hongyue (王紅月), aged 47, is our executive Director and our chief financial officer. She is primarily responsible for the overall financial management and capital investment of the Company. She joined the Company in February 1996 and worked in our finance department from January 1996 to December 1999. She became the head of our finance department in January 2000. Ms. Wang was appointed as an executive Director in April 2013 and after the Company was converted into a joint stock limited liability company, she was appointed as an executive Director again and as chief financial officer in September 2014. Ms. Wang also served as our Supervisor from September 2011 to April 2013. Prior to joining the Company, from July 1994 to December 1995, she worked in the finance department of Wenzhou City Kangning Medicine Wholesale Company of Longwan District (溫州市龍灣區康寧醫藥批發公司), which engages in the medicine wholesale business, where she was responsible for accounting work. Ms. Wang graduated from Online Education College of Xi'an Jiaotong University (西安交通大學網絡教育學院), through long-distance education, with a bachelor's degree in accounting in July 2007. She graduated from Shanghai University of Finance and Economics with a master's degree in EMBA in May 2017. Ms. Wang is the sister of Ms. WANG Lianyue, the spouse of Mr. XU Yi and the sister-in-law of Mr. GUAN Weili.

As at the date of this announcement, Ms. Wang was deemed to have an interest in 5,527,350 Domestic Shares (of which 3,984,350 Domestic Shares were beneficially owned and 1,543,000 Domestic Shares were in the interest in a controlled corporation) and 309,000 H shares within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong).

Non-executive Directors

Mr. YANG Yang (楊揚), aged 64, is our non-executive Director. He is primarily responsible for overseeing the corporate development and strategic planning of the Company. He joined the Company in April 2015 and has served as our non-executive Director since then. Since January 2010, Mr. Yang has also been serving as an executive director of GL Capital Investments Hong Kong Limited (德福資本投資香港有限公司), a company engaging in private equity services for investment business, where he is primarily responsible for hospital management and investments. Prior to joining the Company, from May 1988 to December 2009, Mr. Yang served as the general manager of Long Nice Industries Limited (長立實業有限公司), a company in Hong Kong engaging in the business of trading and the provision of investment services, where he was primarily responsible for businesses involving investment, foreign trade and manufacturing. Mr. Yang graduated from the Naval College of the Chinese People's Liberation Army (中國人民解放軍海軍學院) in Nanjing in March 1982, majoring in operational commanding.

Mr. LIN Lijun (林利軍), aged 47, is our non-executive Director. He is primarily responsible for supervising and providing independent judgment to our Board. He joined the Company in June 2017 and has served as our non-executive Director since then. Mr. Lin has been the partner of Loyal Valley Innovation Capital (正心谷創新資本) since July 2015. Since April 2020, Mr. Lin has been an independent director of Zhejiang Doyin Pump Industry Co., Ltd. (stock code: 002793.SZ). He has been a non-executive director of Akeso, Inc. (stock code: 09926.HK) since November 2019. He has been a non-executive director of InnoCare Pharma Limited. (stock code: 009969.HK) since November 2018. Since June 2018, he has been a non-executive director of Shanghai Junshi Biosciences Co., Ltd. (stock code: 01877.HK).

Association. Since November 2019, he has been serving as a deputy director in Psychosomatic Medicine Professional Branch, Chinese Medical Doctor Association. Mr. Zhao graduated from Kunming Medical University (formerly known as Kunming Medical College) with a bachelor's degree in medicine in July 1983. In August 1988, he graduated from Sichuan University (formerly known as West China University of Medical Sciences) with a master's degree in medicine. In November 1993, he graduated from Heidelberg University in Germany with a doctoral degree in medicine.

Ms. Zhong Wentang (鐘文堂), aged 31, has been serving as a partner at the Department of Compliance Consultation, Shanghai Infaith Consulting Co., Ltd. (上海信公企業管理諮詢有限公司) since February 2019, a company engaging in providing consultation services for listed companies, and is mainly responsible for business in compliance consultation. From February 2016 to February 2019, Ms. Zhong served as a senior consultation manager and consultation business director successively in Shanghai Infaith Consulting Co., Ltd., mainly responsible for business in compliance consultation. From October 2012 to February 2016, she served as an auditor and senior auditor successively in PricewaterhouseCoopers Zhong Tian CPAs Limited Company, mainly responsible for finance and audit for internal control. Ms. Zhong graduated from Fudan University in Shanghai with a bachelor's degree in sociology in June 2012.

Mr. Liu Ning (劉寧) has been serving as a partner at the Department of Compliance Consultation, Shanghai Infaith Consulting Co., Ltd. (上海信公企業管理諮詢有限公司) since February 2019, a company engaging in providing consultation services for listed companies, and is mainly responsible for business in compliance consultation. From February 2016 to February 2019, Mr. Liu served as a senior consultation manager and consultation business director successively in Shanghai Infaith Consulting Co., Ltd., mainly responsible for business in compliance consultation. From October 2012 to February 2016, he served as an auditor and senior auditor successively in PricewaterhouseCoopers Zhong Tian CPAs Limited Company, mainly responsible for finance and audit for internal control. Mr. Liu graduated from Fudan University in Shanghai with a bachelor's degree in sociology in June 2012.

As of the date of this announcement, the positions hold by the candidates for directors of the third session of the Board in members of the Group are as follows:

Proposed Directors	Members of the Group	Positions Held at Members of the Group	Term of Office
GUAN Weili	Qingtian Kangning Hospital Co., Ltd.	Executive director	From April 2011 to present
	Cangnan Kangning Hospital Co., Ltd.	Executive director	From June 2012 to present
	Yongjia Kangning Hospital Co., Ltd.	Executive director	From December 2012 to present
	Yueqing Kangning Hospital Co., Ltd.	Executive director	From September 2013 to present
	Shenzhen Yining Hospital Co., Ltd.	Executive director	From September 2014 to present
	Beijing Yining Hospital Co., Ltd.	Chairman	From August 2015 to present
	Wenzhou Yining Geriatric Hospital Co., Ltd.	Executive director	From November 2015 to present
	Pingyang Kangning Hospital Co., Ltd.	Executive director	From November 2015 to present
	Shenzhen Yining Medical Investment Co., Ltd.	Executive director, general manager	From September 2015 to present
	Quzhou Yining Hospital Co., Ltd.	Executive director	From November 2015 to present
	Wenzhou Lucheng Yining Hospital Co., Ltd.	Chairman, general manager	From April 2020 to present

WANG Lianyue
Executive director

From 2015 to present

0.025 Tw 23.622 0 Td(Chairman)Tj0.025 Tw 13.498 0 Td(FrDr 2015)Tj15
72cd(Chairman)Tj0.025 Tw 13.498 0 Td(From August 2015)Tj0 -1.042 TD()-7252 Td(Yo9)TJ-37.12 -1.042 Td(Wenzhoesent)TJ-379

APPENDIX II – BIOGRAPHICAL DETAILS OF THE PROPOSED SUPERVISORS

Shareholder Representative Supervisor

Ms. HUANG Jingou (黃靖歐), aged 41, is our Supervisor. She is primarily responsible for supervising our daily operations and management. Ms. Huang joined the Company in April 2013 and has served as our Supervisor since then. She was again appointed as a Supervisor in September 2014 after the Company was converted into a joint stock limited liability company. Since November 2011, Ms. Huang has been serving as the investment director of GL Capital (德福資本), which is a company engaging in private equity investment, where she is primarily responsible for investment. Prior to joining the Company, from August 2009 to November 2011, she served as the project director of the China Medical Board (美國中華醫學基金會), which is a trust foundation in the U.S. focusing on medical charity affairs, where she was primarily responsible for project implementation. From June 2003 to December 2006, she was an attorney at Woo Kwan Lee & Lo (胡關李羅律師行) where she was primarily responsible for various legal affairs. Ms. Huang graduated from Sun Yat-Sen University (中山大學)

iJurilr 21.10

QIANy. C thg(hngou)TJT 1 Tf0 Tc Q T1w